57 reports

Major imports include biotechnology vaccines, CSF, r-EPO, recombinant human insulin, recombinant human growth hormones, recombinant interferon, and other biotechnology pharmaceuticals.

  • Breast Cancer
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd

Gland Surgery; ##(##): ##-## Zhang P, et al. (2016).

  • Breast Cancer
  • Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group
  • Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
  • 9 Appendix

Subjects were randomized in a ##:##:## ratio to receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Breast Cancer
  • Market Size
  • AstraZeneca PLC
  • Genentech, Inc.
  • Novartis AG

When compared with the control samples, the tissue taken from the people who had received the reovirus had higher levels of interferons, proteins that ' switch-on' the body' s immune system.

  • Breast Cancer
  • United Kingdom
  • Cancer Research Technology Limited
  • Merck & Co., Inc.
  • Merck Serono S.A.

The one that everyone focuses on is efficacy, and the second one is absolutely safety.

  • Breast Cancer
  • Targeted Therapy
  • United States
  • AbbVie Inc.
  • Pfizer Inc.

Metastatic Hepatocellular Carcinoma (HCC) Cytokine signaling: interferon receptors Interferon Alpha/ Beta Receptor ## (Cytokine Receptor Class II Member ## or Cytokine Receptor Family ## Member ## or Type I Interferon Receptor ## or IFNAR

  • Breast Cancer
  • Market Size
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Merck & Co., Inc.

HOFFMANN-LA ROCHE: GEOGRAPHICAL SEGMENTATION OF TARCEVA 2015 US ##% Roferon-A contains the active substance interferon alfa-##a, which inhibits the growth of types of tumor cells.

  • Breast Cancer
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.

Sumiferon (interferon alfa-n##) ##.

  • Breast Cancer
  • Chemotherapy
  • North America
  • United States
  • Roche Group

IN ADDITION, GLIVEC IS APPROVED IN OVER ## COUNTRIES FOR THE TREATMENT OF ADULT PATIENTS WITH PH+ CML IN BLAST CRISIS, ACCELERATED PHASE OR IN CHRONIC PHASE AFTER FAILURE OF INTERFERON-ALPHA THERAPY.

  • Breast Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

SUMIFERON (INTERFERON ALFA-N##) ##.

  • Breast Cancer
  • Chemotherapy
  • North America
  • United States
  • Roche Group

Sumiferon (interferon alfa-n##) ##.

  • Breast Cancer
  • North America
  • United States
  • Biocon Limited
  • Roche Group
  • Breast Cancer Therapeutics Market, Global, Pipeline Products, Preclinical, 2015

ua: ##.

  • Breast Cancer
  • Market Size
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.

Using a genetically engineered mouse model, DePinho' s team demonstrated how KRAS reduced expression of interferon regulatory factor ## (IRF##).

  • Breast Cancer
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • Dompe Farmaceutici S.p.A.

At low, nonapoptotic concentrations, it inhibits the production of proinflammatory cytokines such as tumor necrosis factor- (TNF-), interleukin-## (IL-##), IL-## and interferon-gamma.

  • Breast Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Incyte Corporation
  • Vendor landscape

You can easily book an appointment with one online.

  • Breast Cancer
  • Alcon, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.

The majority of AEs were grade ##/ ##.

  • Breast Cancer
  • Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

Biopsies all showed sustained (greater than ## months) production of interferon-gamma.

  • Breast Cancer
  • Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

During virus entry of the cell, the ZIKV/ Gas## complex activates AXL kinase activity, which dampens the interferon response to the virus and facilitates infection.

  • Breast Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Breast Cancer
  • Clinical Trial
  • Drug Development
  • World
  • Product Initiative

DIRECT BINDING OF CDNS TO STING INITIATES A SIGNALING CASCADE THROUGH THE TBK-##/ IRF-## AXIS TO INDUCE TYPE I INTERFERON AND OTHER CO-REGULATED GENES GENERATING IMMUNE RESPONSE AGAINST THE TUMOR CELLS.

  • Breast Cancer
  • Colony Stimulating Factor
  • Medical Biotechnology
  • Therapy
  • BriaCell Therapeutics Corp.

Each unit is comprised of one (##) common share and one-half (##/ ##) of a common share purchase warrant exercisable at USD##. ## per share for a period of three (##) years.

  • Breast Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Amgen Inc.

DIRECT BINDING OF CDNS TO STING INITIATES A SIGNALING CASCADE THROUGH THE TBK-##/ IRF-## AXIS TO INDUCE TYPE I INTERFERON AND OTHER CO-REGULATED GENES GENERATING IMMUNE RESPONSE AGAINST THE TUMOR CELLS.

  • Breast Cancer
  • Colony Stimulating Factor
  • Medical Biotechnology
  • Therapy
  • BriaCell Therapeutics Corp.
  • BREAST CANCER, GLOBAL, KEY FEATURES OF
  • BREAST CANCER, GLOBAL, PIPELINE PROGRAMS TARGETING CLUSTER OF DIFFERENTIATION 278 (CD278), 2018

The primary function of STING is to initiate the strong interferon ## type (IFN) immune response to the presence of foreign DNA or damaged host DNA epitopes.

  • Breast Cancer
  • Cancer
  • Monoclonal Antibody
  • Pathology
  • Therapy

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## ## Amgen Inc ## ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## ## Sanofi ## ## ##

  • Breast Cancer
  • Cancer
  • Clinical Trial
  • Therapy
  • World
  • BO-112 - DRUG PROFILE
  • MCT-465 - DRUG PROFILE

These include its induction of interferons, immune enhancing effect, its activation of specific enzymes.

  • Breast Cancer
  • Clinical Trial
  • Hospital
  • Therapy
  • Hemispherx Biopharma, Inc.
  • BO-112 - DRUG PROFILE
  • MCT-465 - DRUG PROFILE

These include its induction of interferons, immune enhancing effect, its activation of specific enzymes.

  • Breast Cancer
  • Clinical Trial
  • Hospital
  • Therapy
  • Hemispherx Biopharma, Inc.

Using a genetically engineered mouse model, DePinho' s team demonstrated how KRAS reduced expression of interferon regulatory factor ## (IRF##).

  • Breast Cancer
  • Immunotherapy
  • United States
  • World
  • Product Initiative

DIRECT BINDING OF CDNS TO STING INITIATES A SIGNALING CASCADE THROUGH THE TBK-##/ IRF-## AXIS TO INDUCE TYPE I INTERFERON AND OTHER CO-REGULATED GENES GENERATING IMMUNE RESPONSE AGAINST THE TUMOR CELLS.

  • Breast Cancer
  • Cancer
  • United States
  • World
  • Product Initiative

Using a genetically engineered mouse model, DePinho' s team demonstrated how KRAS reduced expression of interferon regulatory factor ## (IRF##).

  • Breast Cancer
  • Immunotherapy
  • United States
  • World
  • Product Initiative

Each unit will be comprised of one common share of the company and one common share purchase warrant.

  • Biotechnology
  • Breast Cancer
  • Pharmaceutical
  • United States
  • Oncolytics Biotech Inc.